SPIB and Waldenstrom macroglobulinemia: Our results revealed that Ezh2 inhibition increases PRDM1 and downregulates SPIB, suggesting that further investigation of Ezh2 inhibitors in the context of ABC DLBCL and Waldenstrom macroglobulinaemia could be informative.